BR112014032579A2 - formulação de fenofibrato - Google Patents

formulação de fenofibrato

Info

Publication number
BR112014032579A2
BR112014032579A2 BR112014032579A BR112014032579A BR112014032579A2 BR 112014032579 A2 BR112014032579 A2 BR 112014032579A2 BR 112014032579 A BR112014032579 A BR 112014032579A BR 112014032579 A BR112014032579 A BR 112014032579A BR 112014032579 A2 BR112014032579 A2 BR 112014032579A2
Authority
BR
Brazil
Prior art keywords
granules
fenofibrate
water
vivo
surfactant
Prior art date
Application number
BR112014032579A
Other languages
English (en)
Inventor
Alan Shaw Andrew
Allen Redelman Glenn
C Chattaraj Sarat
Original Assignee
Mylan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Inc filed Critical Mylan Inc
Publication of BR112014032579A2 publication Critical patent/BR112014032579A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

abstract: title fenofibrate formulation various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. the first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative. ________________________________________________________________________ tradução do resumo resumo patente de invenção: "formulação de fenofibrato". trata-se de várias composições de fenofibrato que incluem uma pluralidade de primeiros grânulos que têm uma alta biodisponibilidade in vivo e uma pluralidade de segundos grânulos que tem uma baixa biodisponibilidade in vivo. os primeiros grânulos podem compreender fenofibrato, de 0,3% a 10%, em peso, dos primeiros grânulos de um primeiro tensoativo e um primeiro derivado de celulose solúvel em água ou dispersível em água e os segundos grânulos podem compreender fenofibrato, de 0% a 0,25%, em peso, dos segundos grânulos de um segundo tensoativo e um segundo derivado de celulose solúvel em água ou dispersível em água.
BR112014032579A 2012-06-25 2012-06-25 formulação de fenofibrato BR112014032579A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/043971 WO2014003706A1 (en) 2012-06-25 2012-06-25 Fenofibrate formulation

Publications (1)

Publication Number Publication Date
BR112014032579A2 true BR112014032579A2 (pt) 2017-06-27

Family

ID=49783663

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032579A BR112014032579A2 (pt) 2012-06-25 2012-06-25 formulação de fenofibrato

Country Status (5)

Country Link
EP (1) EP2863890A4 (pt)
BR (1) BR112014032579A2 (pt)
CA (1) CA2877901A1 (pt)
IN (1) IN2014DN11044A (pt)
WO (1) WO2014003706A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101925590B1 (ko) * 2016-08-30 2018-12-05 대원제약 주식회사 개선된 생체이용률을 갖는 페노피브릭산 제제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US7863331B2 (en) 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
BRPI0606883A2 (pt) * 2005-02-10 2009-12-01 Lifecycle Pharma As composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
US20090252787A1 (en) * 2006-07-28 2009-10-08 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
FR2940118B1 (fr) * 2008-12-24 2013-08-09 Ethypharm Sa Formulation pharmaceutique de fenofibrate nanonise
WO2010078429A1 (en) * 2008-12-30 2010-07-08 Impax Laboratories, Inc. Pharmaceutical dosage forms and methods of manufacturing same
US20110217369A1 (en) * 2009-09-03 2011-09-08 Ranbaxy Laboratories Limited Fenofibrate compositions

Also Published As

Publication number Publication date
WO2014003706A1 (en) 2014-01-03
IN2014DN11044A (pt) 2015-09-25
EP2863890A4 (en) 2015-12-09
EP2863890A1 (en) 2015-04-29
CA2877901A1 (en) 2014-01-03

Similar Documents

Publication Publication Date Title
BR112016013201A2 (pt) administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para edição de genoma
CL2016000188A1 (es) Composiciones de arní de serpinc1 y métodos de uso de las mismas
BR112017018260A2 (pt) éteres de celulose esterificados solúveis água tendo um baixo grau de neutralização
TR201906255T4 (tr) Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar.
BR112013005679A2 (pt) imidazopiridazinas substituídas
BR112015032340A2 (pt) composições e artigos para cuidados pessoais
BR112015021923A2 (pt) composições de limpeza contendo uma polieteramina, um polímero removedor de sujeiras e uma carboximetil-celulose
MX362792B (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados.
BR112014026703A2 (pt) inibidores de dna-pk
BR112014029185A2 (pt) nucleosídeos de spirooxetano uracila
BRPI1102843B8 (pt) Composições de limpeza límpidas, de baixa irritação com ph relativamente baixo
TR200806298A2 (tr) Farmasötik formülasyon
BR112015014065A2 (pt) éter de celulose esterificado, composição, dispersão sólida, forma de dosagem e invólucro de cápsula
BR112014003139A2 (pt) musgo de turfa umectável resistente à lixiviação, método de preparação, e método de uso
WO2012052536A3 (en) Cosmetic composition comprising aloe vera and an isethionic acid derivative
BR112013029920A2 (pt) composição de cobertura misturável, cobertura de mistura, uso da composição de cobertura misturável e método para preparar a composição de cobertura misturável
BR112017018367A2 (pt) gelificação de éteres de celulose esterificados
BR112018012966A2 (pt) composições de alimento para animais de estimação
MX2016000727A (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservante.
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
RS54584B1 (en) 15-HEPE PREPARATIONS AND PROCEDURES FOR THEIR USE
BR112012031882A2 (pt) dispersão sólida de tolvaptan e seu método de preparação
BR112014011781A2 (pt) agente oleoso de usinagem solúvel em água, fluido de usinagem e método de usinagem
BR112015001728B8 (pt) composições de condicionador
BR112015012968A2 (pt) composições e métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure
B07A Technical examination (opinion): publication of technical examination (opinion)
B09B Decision: refusal
B09B Decision: refusal

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL